Raymond James & Associates’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Raymond James & Associates’s Portfolio FTXH Stock Details FTXH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-11,336	Closed	-$296K	–	3884
2023 Q1	$296K	Sell	11,336 -3,237	-22%	-$86.8K	﹤0.01%	3254
2022 Q4	$400K	Sell	14,573 -110,452	-88%	-$2.94M	﹤0.01%	3038
2022 Q3	$3.01M	Buy	+125,025	New	+$3.23M	﹤0.01%	1719

Other funds holding FTXH

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

WFA

WMG Financial Advisors Knoxville, Tennessee $265M AUM 26.03% 1-Year Est. Return

KNW

Kesler Norman & Wride Ogden, Utah $631M AUM 27.63% 1-Year Est. Return

PPWM

Paragon Private Wealth Management Lexington, Kentucky $320M AUM 23.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

OMC

Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Raymond James & Associates's FTXH Position: Q2 2023 in Review

Raymond James & Associates sold out of First Trust Nasdaq Pharmaceuticals ETF (FTXH) in Q2 2023, closing a stake of 11,336 shares — an estimated $296K sold.

Raymond James & Associates first reported a position in FTXH in Q3 2022 and held it in 3 quarters. The position peaked at $3.01M in Q3 2022. 25 funds tracked by Wall St. Rank hold FTXH as of Q2 2023.

Raymond James & Associates reported no remaining First Trust Nasdaq Pharmaceuticals ETF position as of Q2 2023 after selling out during the quarter.
Raymond James & Associates sold 11,336 First Trust Nasdaq Pharmaceuticals ETF shares in Q2 2023, an estimated $296K.
Raymond James & Associates first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q3 2022 and held it in 3 quarters.
Raymond James & Associates's First Trust Nasdaq Pharmaceuticals ETF position peaked at $3.01M in Q3 2022.
25 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q2 2023.

Based on Raymond James & Associates's 13F filing for Q2 2023, filed 25 Jul 2023.